Marshall Wace LLP Makes New Investment in Krystal Biotech, Inc. (NASDAQ:KRYS)

Marshall Wace LLP acquired a new stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 10,331 shares of the company's stock, valued at approximately $1,618,000.

Other large investors have also made changes to their positions in the company. Wilmington Savings Fund Society FSB acquired a new position in shares of Krystal Biotech during the 3rd quarter worth approximately $40,000. Covestor Ltd increased its position in Krystal Biotech by 972.7% during the fourth quarter. Covestor Ltd now owns 708 shares of the company's stock worth $111,000 after purchasing an additional 642 shares during the last quarter. Avanza Fonder AB purchased a new stake in shares of Krystal Biotech during the 4th quarter valued at approximately $119,000. KBC Group NV lifted its stake in shares of Krystal Biotech by 46.3% in the 4th quarter. KBC Group NV now owns 939 shares of the company's stock valued at $147,000 after purchasing an additional 297 shares during the last quarter. Finally, Blue Trust Inc. raised its stake in shares of Krystal Biotech by 74.4% in the 4th quarter. Blue Trust Inc. now owns 1,015 shares of the company's stock valued at $159,000 after acquiring an additional 433 shares during the period. 86.29% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the sale, the insider now owns 1,463,711 shares of the company's stock, valued at approximately $260,233,178.69. The trade was a 1.68 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Kathryn Romano sold 750 shares of the stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the transaction, the chief accounting officer now directly owns 12,604 shares in the company, valued at $2,208,472.88. The trade was a 5.62 % decrease in their position. The disclosure for this sale can be found here. 13.70% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. HC Wainwright increased their target price on shares of Krystal Biotech from $221.00 to $240.00 and gave the stock a "buy" rating in a report on Monday. Chardan Capital increased their price objective on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a research report on Thursday, February 20th. Citigroup upped their price target on Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a report on Thursday, February 20th. Cantor Fitzgerald reiterated an "overweight" rating and set a $215.00 target price on shares of Krystal Biotech in a research report on Thursday, February 20th. Finally, Jefferies Financial Group initiated coverage on shares of Krystal Biotech in a research note on Wednesday, March 5th. They set a "buy" rating and a $245.00 target price for the company. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $222.71.

Krystal Biotech Trading Up 0.3 %

Shares of Krystal Biotech stock traded up $0.47 during mid-day trading on Friday, hitting $166.16. 228,173 shares of the stock were exchanged, compared to its average volume of 294,918. The company has a 50-day simple moving average of $175.22 and a 200 day simple moving average of $171.38. The stock has a market capitalization of $4.80 billion, a price-to-earnings ratio of 55.57 and a beta of 0.75. Krystal Biotech, Inc. has a twelve month low of $141.72 and a twelve month high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.29 by $0.23. The business had revenue of $91.10 million for the quarter, compared to analysts' expectations of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company's quarterly revenue was up 116.4% on a year-over-year basis. During the same period last year, the company earned $0.30 earnings per share. Equities research analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).